CN Bio
CN Bio is a leading organ-on-a-chip (OOC) company based in Cambridge, UK. CN Bio offers a portfolio of products and services to optimise the accuracy and efficiency of bringing new medicines to market; providing significant savings in cost and time to drug discovery and development pipelines.With more than a decade of experience in precision engineering and single and multi-organ microphysiology, CN Bio aims to transform the way human-relevant pre-clinical data is generated through the development of advanced, predictive human organ models. The Company’s PhysioMimix® OOC range of microphysiological systems (MPS) bridges the relevance gap between traditional cell culture, in vivo animal studies, and human trials by advancing towards the simulation of human biological conditions. The technology provides deep mechanistic insights to enable researchers to refine preclinical study design, reducing the number of animals required, and better preparing and informing studies ahead of the clinic to support safe, efficacious and efficient therapeutic development.Content by CN Bio
Explore the role of microphysiological systems in advancing human-relevant liver toxicity testing and mechanistic evaluation.
Explore approaches to evaluate complex drug-induced liver injury and improve confidence in safety assessment.
Learn how various 3D cell culture systems differ in design, function, and application in biomedical research.
| 2 min read
The launch marks a major step toward more predictive, human-relevant drug development using microphysiological systems.
Microphysiological systems capture the complexity of human liver biology, addressing one of drug development’s most persistent challenges.
Available on Demand
Discover a human-relevant model that closes the gap between in vitro drug metabolism testing and clinical outcomes.
Available on Demand
Why do some drugs struggle to reach their target tissue? Discover how microphysiological systems, when combined with computational modeling, is able to predict human oral bioavailability.
| 2 min read
Two new animal microphysiological system models have been introduced to improve the translatability of preclinical drug safety assessments by enabling early, comparative evaluation of hepatotoxicity across human, rat, and dog Liver-on-a-chip models.
Explore how a dual-organ microphysiological system connects human gut and liver tissue to bridge gaps in predicting how drugs behave in the body.
Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Available on Demand
Microphysiological systems offer a promising solution to the long-standing challenge of predicting clinical drug safety outcomes from preclinical models.
Discover how scalable, high-content liver-on-a-chip models improve drug safety evaluation in early development.
